Planned introduction of patient-friendly pen auto-injector in 2019 designed to increase comfort and convenience of treatment across the entire Akari subcutaneous program Second eculizumab-resistant patient with paroxysmal nocturnal haemoglobinuria (PNH) successfully treated with Coversin for more

Highlights potential role of both complement and leukotriene pathways in a therapeutic mouse model of rheumatoid arthritis (RA) NEW YORK and LONDON , Nov. 15, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat

Four ongoing clinical trial programs Two clinical programs expected to report initial data in first quarter 2019 Long-term clinical study continues to yield encouraging safety data NEW YORK and LONDON , Nov. 15, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical

Coversin, a first-in-class combined complement C5 and leukotriene B4 (LTB4) inhibitor, is currently being developed to treat four orphan diseases: Thrombotic microangiopathies (TMAs) Bullous pemphigoid (BP) Atypical keratoconjunctivits (AKC) Paroxysmal nocturnal hemoglobinuriua (PNH) All four

Announced Securities Purchase Agreement For Up To $20 Million with Aspire Capital Fund, LLC NEW YORK and LONDON , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to

NEW YORK and LONDON , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics , Plc (“Akari” or the “Company”) (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement

NEW YORK and LONDON , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX) (“Akari” or “the Company”), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement

Combined inhibition of LTB4 and C5 by Coversin showed reversal of disease symptoms in preclinical rheumatoid arthritis (RA) model Ex vivo data from bullous pemphigoid (BP) patients showed presence of both LTB4 and C5 at similar elevated concentrations These new data support the potential advantage

Opened three clinical trials in 2018 Trials in which complement dysregulation is the primary disease driver CAPSTONE, the Phase III trial in naïve paroxysmal nocturnal hemoglobinuria (PNH), in which patient treatment has commenced Phase II U.S. trial for PNH patients resistant to treatment with

NEW YORK and LONDON , June 15, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today announces it will be presenting an